The effect of substance P on nitric oxide release in a rheumatoid arthritis model

Inflammation Research

Volumn 55, Issue 6, 2006, Pages 236-240

  O'Shaughnessy, M C ^a   Vetsika, E K ^a   Inglis, J J ^a   Carleson, J ^b   Haigh, R ^c   Kidd, B L ^a   Winyard, P G ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Neurogenic inflammation; Neurokinin receptor; Nitric oxide; Rheumatoid arthritis; Substance P

Indexed keywords

INTERLEUKIN 1BETA; NEUROKININ 1 RECEPTOR; NITRATE; NITRIC OXIDE; NITRITE; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY ELECTROPHORESIS; CELL CULTURE; CONTROLLED STUDY; FEMALE; FOOT PAD; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; RHEUMATOID ARTHRITIS; SWELLING; SYNOVIOCYTE;

AGED; ANIMALS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MICE; MICE, KNOCKOUT; MIDDLE AGED; NEUROTRANSMITTER AGENTS; NITRATES; NITRIC OXIDE; NITRITES; RECEPTORS, NEUROKININ-1; SUBSTANCE P; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748502083     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-006-0079-8     Document Type: Article

References (45)

1. Maggi CA. The effects of tachykinins on inflammatory and immune cells. Regul Pept 1997; 70: 75-90.
2. Westermark T, Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Kjorell U, Forsgren S. Increased content of bombesin/GRP in human synovial fluid in early arthritis: different pattern compared with substance P. Clin Exp Rheumatol 2001; 19: 715-20.
3. Ferrell WR, Russell NJ. Extravasation in the knee induced by antidromic stimulation of articular C fibre afferents of the anaesthetized cat. J Physiol 1986; 379: 407-16.
4. Hartung HP, Toyka KV. Activation of macrophages by substance P: induction of oxidative burst and thromboxane release. Eur J Pharmacol 1983; 89: 301-5.
5. Simmons MA, Brodbeck RM, Karpitskiy VV, Schneider CR, Neff DP, Krause JE. Molecular characterization and functional expression of a substance P receptor from the sympathetic ganglion of Rana catesbeiana. Neuroscience 1997; 79: 1219-29.
6. Colten HR, Krause JE. Pulmonary inflammation: a balancing act. N Engl J Med 1997; 336: 1094-9.
7. Scicchitano R, Stanisz AM, Payan DG, Kiyono H, McGhee JR, Bienenstock J. Expression of substance P and somatostatin receptors on a T helper cell line. Adv Exp Med Biol 1987; 216: 185-90.
8. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988; 241: 1218-21.
9. 1) gene expression in synovial tissue in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1998; 27: 135-41.
10. Lloyds D, Brindle NP, Hallett MB. Priming of human neutrophils by tumour necrosis factor-alpha and substance P is associated with tyrosine phosphorylation. Immunology 1995; 84: 220-6.
11. 1 receptors. J Cardiovasc Pharmacol 2003; 41: 343-55.
12. Evans CH, Stefanovic-Racic M. Nitric oxide in arthritis. Methods 1996; 10: 38-42.
13. Ralston SH. The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas! Br J Rheumatol 1997; 36: 831-8.
14. Bush PA, Gonzalez NE, Griscavage JM, Ignarro LJ. Nitric oxide synthase from cerebellum catalyzes the formation of equimolar quantities of nitric oxide and citrulline from L-arginine. Biochem Biophys Res Commun 1992; 185: 960-6.
15. Ialenti A, Moncada S, Di Rosa M. Modulation of adjuvant arthrtis by endogenous nitric oxide. Br J Pharmacol 1993; 110: 701-6.
16. Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK et al. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 1995; 273: 15-24.
17. Lippe IT, Stabentheiner A, Holzer P. Participation of nitric oxide in the mustard oil-induced neurogenic inflammation of the rat paw skin. Eur J Pharmacol 1993; 232: 113-20.
18. Salvemini D, Wang ZQ, Wyatt PS, Bourdon DM, Marino MH, Manning PT et al. Nitric oxide: a key mediator in the early and late phase of carrageeenan-induced rat paw inflammation. Br J Pharmacol 1996; 118: 829-38.
19. Hukkanen M, Platts LAM, Haralamous S, Ainola M, Konttinen YT, Kollias G et al. Induction of inducible nitric oxide synthase, argininosuccinate synthase, and GTP cyclohydrolase I in arthritic joints of tumour necrosis factor-alpha transgenic mice. J Rheumatol 2003; 30: 652-9.
20. Carleson J, Bileviciute I, Theodorsson E, Appelgren B, Appelgren A, Yousef N et al. Effects of adjuvant on neuropeptide-like immunoreactivity in the temporomandibular joint and trigeminal ganglia. J Orofac Pain 1997; 11: 195-9.
21. Lundeberg T, Alstergren P, Appelgren A, Appelgren B, Carleson J, Kopp S et al. A model for experimentally induced temeromandibular joint arthritis in rats: effects of carrageenan on neuropeptide-like immunoreactivity. Neuropeptides 1996; 30: 37-41.
22. Andoh T, Kuraishi Y. Nitric oxide enhances substance P-induced itch-associated responses in mice. Br J Pharmacol 2003; 138: 202-8.
23. Yonehara N, Yoshimura M. Interaction between nitric oxide and substance P on heat-induced inflammation in rat paw. Neurosci Res 2000; 36: 35-43.
24. Konttinen YT, Tian-Fang L, Hukkanen M, Ma J, Xu JW, Virtanen I. Fibroblast biology. Signals targeting the synovial fibroblast in arthritis. Arthritis Res 2000; 2: 348-55.
25. Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K et al. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 1995; 96: 2357-63.
26. McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, Sturrock RD et al. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med 1996; 184: 1519-24.
27. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and (15N) nitrate in biological fluids. Anal Biochem 1982; 126: 131-8.
28. Ignarro LJ, Fukuto JM, Griscavage JM, Rogers NE, Byrns RE. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from L-arginine. Proc Natl Acad Sci U S A 1993; 90: 8103-7.
29. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJ et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998; 392: 394-7.
30. Hood VC, Cruwys SC, Urban L, Kidd BL. The neurogenic contribution to synovial leucocytes infiltration and other outcome measures in a guinea pig model of arthritis. Neurosci Lett 2001; 299: 201-4.
31. Davies C, Perrett D, Zhang Z, Nielsen B, Blake D, Winyard PG. Simultaneous analysis of nitrite, nitrate and the nicotinamide nucleotides by capillary electrophoresis: application to biochemical studies and human extracellular fluids. Electrophoresis 1999; 20: 2111-7.
32. Karan A, Karan MA, Vural P, Erten N, Tascioglu C, Aksoy C, et al. Synovial fluid nitric oxide levels in patients with knee osteoarthritis. Clin Rheumatol 2003; 22: 397-9.
33. Garret C, Carruette A, Fardin V, Moussaoui S, Peyronel JF, Blanchard JC et al. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci USA 1991; 88: 10208-12.
34. Wickstrom HR, Berner J, Holgert H, Hokfelt T, Lagercrantz H. Hypoxic response in newborn rat is attenuated by neurokinin-1 receptor blockade. Respir Physiol Neurobiol 2004; 140: 19-31.
35. 1 receptor is essential for the full expression of noxious inhibitory controls in the mouse. J Neurosci 2001; 21: 1039-46.
36. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201: 167-80.
37. Lambert N, Lescoulie PL, Yassine-Diab B, Enault G, Mazieres B, De Preval C et al. Substance P enhances cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) expression on cultured rheumatoid fibroblast-like synoviocytes. Clin Exp Immunol 1998; 113: 269-75.
38. Grimsholm O, Rantapaa-Dahlqvist S, Forsgren S. Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res 2005; 7: R416-R426.
39. Meier B, Radeke HH, Selle S, Raspe HH, Sies H, Resch K et al. Human fibroblasts release reactive oxygen species in response to treatment with synovial fluids from patients suffering from arthritis. Free Radic Res Commun 1990; 8: 149-60.
40. Elfvin LG, Holmberg K, Johansson J, Aldskogius H. The innervation of the synovium of the knee joint in the guinea pig: an immunohistochemical and ultrastructural study. Anat Embryol (Berl) 1998; 197: 293-303.
41. Stratz T, Muller W. The use of 5-HT3 receptor antagonists in various rheumatic diseases - a clue to the mechanism of action of these agents in fibromyalgia? Scand J Rheumatol Suppl 2000; 113: 66-71.
42. Hrycaj P. Serotonin type 3 receptor antagonist tropisetron in the treatment of chronic inflammatory rheumatic conditions - preliminary clinical experience. Scand J Rheumatol Suppl 2004; 119: 55-8.
43. Farber L, Haus U, Spath M, Drechsler S. Physiology and pathology of 5-HT3 receptor. Scand J Rheumatol Suppl 2004; 119: 2-8.
44. Zhang Z, Naughton D, Winyard PG, Benjamin N, Blake DR, Symons MCR. Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res Commun 1998; 249: 767-72.
45. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nature Med 2003; 9: 1498-505.